Omega-3 Supplementation and Attention-deficit-hyperactivity Disorder (ADHD)

Hadassah Medical Organization40 enrolled

Overview

It is assumed that only 1/5 of children diagnosed with attention-deficit-hyperactivity disorder (ADHD) are treated. New treatment modalities are urgently needed. Omega-3 fatty acids have been used in this setting, yet results are conflicting. The parent omega-3 fatty acid alpha-linolenic acid (ALA) has only been used in one trial. 40 children diagnosed with ADHD will be randomized to consume either ALA or placebo for two months. Baseline and end assessments will include ADHD-related questionnaires and a computerized test. The investigators hypothesize that ALA supplementation will prove beneficial for children with ADHD.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

3 grams of ALA-containing plant oil

PlaceboDIETARY_SUPPLEMENT

Eligibility

Sex: ALLMin age: 6 YearsMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ADHD diagnosis * informed consent Exclusion Criteria: * refusal of any testing * any comorbidities * any medication or supplement use

Locations (1)

Hadassah Medical Organization

Jerusalem, Jerusalem, Israel

Outcomes

Primary Outcomes

ADHD symptoms

scores of DSM and Conners questionnaires

Time frame: 8 weeks

Secondary Outcomes

Computerized test performance

performance in a computerized test of attention

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.